← Back to patent-cliff list
ETX-19477
Tier C — Watch / tradeETX-19477
858 Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PARG
Indications (approved)：Colorectal cancer, Ovarian cancer, Epithelial ovarian cancer, Prostate cancer, Castration-resistant prostate cancer, Breast cancer, Solid tumour, Gastric cancer
Regional status
US
Phase II
2024-05-13
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ETX-19477?
Approved indications include: Colorectal cancer, Ovarian cancer, Epithelial ovarian cancer, Prostate cancer, Castration-resistant prostate cancer, Breast cancer, Solid tumour, Gastric cancer.
When does the ETX-19477 patent expire?
No public expiry year is available for ETX-19477 yet; this page updates once verified.
How do I get a quote for ETX-19477 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01